Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel
Status:
Recruiting
Trial end date:
2023-07-15
Target enrollment:
Participant gender:
Summary
This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I
clinical study in patients with advanced solid tumors. The aim of this study is designed to
evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of
albumin-bound formulation of docetaxel for intravenous infusion in patients with advanced
solid tumors.